According to the NCI website, Teclistamab or anti-CD3/anti-BCMA bispecific monoclonal antibody JNJ-64007957 is a bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)

Link to National Cancer Institute